Title: 2017 ACVIM Forum Research Abstract Program Document date: 2017_6_15
ID: ri2w5iby_209
Snippet: Eighty-five completed surveys were evaluated with responses from oncologists (83.5%) in private practice (73%) with >80% of their practice being medical oncology (70.6%). The oral chemotherapeutics evaluated were associated with a minimal/low (≤50%) risk of acute and delayed vomiting independent of VCOG grade. Injectable chemotherapeutics most associated with moderate/high (>50%) risk of causing clinically significant (≥Grade 2) acute or dela.....
Document: Eighty-five completed surveys were evaluated with responses from oncologists (83.5%) in private practice (73%) with >80% of their practice being medical oncology (70.6%). The oral chemotherapeutics evaluated were associated with a minimal/low (≤50%) risk of acute and delayed vomiting independent of VCOG grade. Injectable chemotherapeutics most associated with moderate/high (>50%) risk of causing clinically significant (≥Grade 2) acute or delayed vomiting included cisplatin, dacarbazine, epirubicin, paclitaxel and streptozocin. Of the nine antiemetics evaluated, maropitant and ondansetron were most frequently administered. Inappetence following chemotherapy administration was most commonly treated with maropitant and mirtazapine.
Search related documents:
Co phrase search for related documents- chemotherapy administration follow and medical oncology: 1
- complete survey and eighty complete survey: 1
- complete survey and medical oncology: 1, 2, 3
- medical oncology and private practice: 1
Co phrase search for related documents, hyperlinks ordered by date